Zymeworks Inc. – NYSE:ZYME

Add to watchlist

$14.1

-0.40

-2.76%

Market closed

Open in about 12 hours

+43.99%

month

+43.99%

quarter

+34.88%

year

Market Cap	954.64M
Enterprise value	225.49M

P/E	4.74
EV/Sales	0.54
EV/EBITDA	1.49
Price/Sales	1.45
Price/Book	1.21
PEG ratio	0.03
EPS	-1.79

Revenue	50.46M
EBITDA	-137.64M
Income	-125.97M
Revenue Q/Q	-71.80%
Revenue Y/Y	-88.68%

Profit margin	30.14%
Oper. margin	31.64%
Gross margin	1.32%
EBIT margin	31.64%
EBITDA margin	-272.75%

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Zymeworks Stock Forecast

M Q Y

Last Year

$18.17

Potential upside: 28.84%

Analysts Price target
Financials & Ratios estimates

Zymeworks Inc. (NYSE:ZYME): Profit margin
Jun 2023	7.00M	-51.15M	-730.53%
Sep 2023	16.50M	-28.68M	-173.8%
Dec 2023	16.92M	-14.48M	-85.56%
Mar 2024	10.03M	-31.65M	-315.58%

Zymeworks Inc. (NYSE:ZYME): Earnings per share (EPS)
2023-03-07	4.84	4.65
2023-05-08	-0.64	-0.37
2023-08-10	-0.51	-0.76
2023-11-07	-0.55	-0.41

Zymeworks Inc. (NYSE:ZYME): Debt to assets
Jun 2023	602054000	153.13M	25.44%
Sep 2023	556366000	132.02M	23.73%
Dec 2023	580880000	116.07M	19.98%
Mar 2024	553752000	115.75M	20.9%

Zymeworks Inc. (NYSE:ZYME): Cash Flow
Jun 2023	-6.39M	-60.67M	27.60M
Sep 2023	-42.66M	-7.02M	1.89M
Dec 2023	13.95M	-1.33M	50.61M
Mar 2024	-37.66M	-7.31M	2.12M

Zymeworks alternative data

Social Media

🎓 Academy: How impactful can social media data be in investment decisions

Zymeworks Inc. (NYSE:ZYME): Employee count
Aug 2023	304
Sep 2023	237
Oct 2023	237
Nov 2023	237
Dec 2023	252
Jan 2024	252
Feb 2024	252
Mar 2024	272
Apr 2024	272
May 2024	272
Jun 2024	275
Jul 2024	275

Zymeworks
Hedge Funds Holdings Q1 2022

94.98% +13.93%

of ZYME is owned by hedge funds

113 +2

hedge funds hold ZYME stock

49.51M +7.17M

shares is hold by hedge funds

ZYME hedge funds holdings changes

Zymeworks Inc. (NYSE:ZYME): Insider trades (number of shares)
Period	Buy	Sel
Jan 2024	0	39697
Dec 2024	1385117	0

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Purchase	27 Dec 2024	ECOR1 CAPITAL, LLC director, 10 percent owner: director, 10 percent owner:	Common Stock	101,659	$14.49	$1,473,141
Purchase	26 Dec 2024	ECOR1 CAPITAL, LLC director, 10 percent owner: director, 10 percent owner:	Common Stock	16,692	$14.38	$240,031
Purchase	24 Dec 2024	ECOR1 CAPITAL, LLC director, 10 percent owner: director, 10 percent owner:	Common Stock	11,958	$14.12	$168,895
Purchase	23 Dec 2024	ECOR1 CAPITAL, LLC director, 10 percent owner: director, 10 percent owner:	Common Stock	251,502	$14.25	$3,584,155
Purchase	20 Dec 2024	ECOR1 CAPITAL, LLC director, 10 percent owner: director, 10 percent owner:	Common Stock	704,488	$14.08	$9,917,782
Purchase	19 Dec 2024	ECOR1 CAPITAL, LLC director, 10 percent owner: director, 10 percent owner:	Common Stock	298,818	$13.53	$4,042,709
Sale	8 Jan 2024	GALBRAITH KENNETH director, officer: Chair & CEO director, officer: Chair & CEO	Common Stock	5,706	$11.22	$63,998
Sale	8 Jan 2024	ASTLE CHRISTOPHER officer: SVP & Chief Financial Officer officer: SVP & Chief Financial ..	Common Stock	1,431	$11.22	$16,050
Sale	8 Jan 2024	MOORE PAUL ANDREW officer: Chief Scientific Officer officer: Chief Scientific Officer	Common Stock	2,339	$11.22	$26,234
Option	5 Jan 2024	GALBRAITH KENNETH director, officer: Chair & CEO director, officer: Chair & CEO	Restricted Stock Unit	47,666	N/A	N/A

Status	Patent	Filling date	Issue date
Application	Application ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATES AND RELATED METHODS Filling date: 2 Jul 2020 Issue date: 18 Aug 2022	2 Jul 2020	18 Aug 2022
Application	Application MODIFIED ANTIGEN BINDING POLYPEPTIDE CONSTRUCTS AND USES THEREOF Filling date: 25 Feb 2022 Issue date: 11 Aug 2022	25 Feb 2022	11 Aug 2022
Application	Application ENGINEERED IMMUNOGLOBULIN HEAVY CHAIN-LIGHT CHAIN PAIRS AND USES THEREOF Filling date: 24 Jan 2022 Issue date: 21 Jul 2022	24 Jan 2022	21 Jul 2022
Grant	Grant Utility: Bispecific antigen-binding constructs targeting Her2 Filling date: 18 Jun 2018 Issue date: 10 May 2022	18 Jun 2018	10 May 2022
Application	Application METHODS OF USING A BISPECIFIC ANTIGEN-BINDING CONSTRUCT TARGETING HER2 FOR THE TREATMENT OF BILIARY TRACT CANCERS Filling date: 19 Nov 2021 Issue date: 5 May 2022	19 Nov 2021	5 May 2022
Grant	Grant Utility: Modified antigen binding polypeptide constructs and uses thereof Filling date: 29 May 2015 Issue date: 19 Apr 2022	29 May 2015	19 Apr 2022
Grant	Grant Utility: Engineered immunoglobulin heavy chain-light chain pairs and uses thereof Filling date: 5 Sep 2018 Issue date: 29 Mar 2022	5 Sep 2018	29 Mar 2022
Grant	Grant Utility: Multivalent heteromultimer scaffold design and constructs Filling date: 21 May 2019 Issue date: 15 Feb 2022	21 May 2019	15 Feb 2022
Application	Application BISPECIFIC ANTIGEN-BINDING CONSTRUCTS TARGETING HER2 Filling date: 24 Feb 2021 Issue date: 30 Dec 2021	24 Feb 2021	30 Dec 2021
Grant	Grant Utility: Antibodies comprising C-terminal light chain polypeptide extensions and conjugates and methods of use thereof Filling date: 23 Dec 2014 Issue date: 28 Dec 2021	23 Dec 2014	28 Dec 2021

Zymeworks
Earnings Call Transcripts

Quarter	Transcript
Q1 2024 2 May 2024	Q1 2024 Earnings Call Transcript
Q4 2023 6 Mar 2024	Q4 2023 Earnings Call Transcript
Q3 2023 7 Nov 2023	Q3 2023 Earnings Call Transcript
Q2 2023 10 Aug 2023	Q2 2023 Earnings Call Transcript

ZYME earnings call transcripts

Zymeworks
Executives

Insider	Age	Compensation
Dr. Ali Tehrani (1972) Co-Founder, Pres, Chief Executive Officer & Director	53	$877,660
Dr. Anthony J. Polverino Ph.D. (1963) Chief Scientific Officer & Executive Vice President of Early Devel.	62	$606,710
Mr. Neil A. Klompas C.A., CPA, CPA, CA (1972) Executive Vice President of Bus. Operations & Chief Financial Officer	53	$589,860
Ms. Kathryn O'Driscoll (1964) Chief People Officer	61	$497,220

Zymeworks
Latest News

Thursday, 19 December 2024
09:00	Zymeworks: Prime Time For Ziihera, Early-Stage Pipeline Progressing Ahead Of Schedule	seekingalpha.com
Monday, 16 December 2024
05:22	Zymeworks upgraded to Overweight from Neutral at JPMorgan	https://thefly.com
Thursday, 21 November 2024
06:05	Zymeworks Announces Participation in Upcoming Investor Conferences	globenewswire.com
06:00	FDA Grants U.S. Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)	globenewswire.com
Tuesday, 5 November 2024
06:00	Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW191 in Folate Receptor-⍺ Expressing Advanced Solid Tumors	globenewswire.com
Monday, 4 November 2024
04:28	Zymeworks: Turning The Tide With 2 Key Milestones For Zanidatamab	seekingalpha.com
Thursday, 31 October 2024
22:05	Zymeworks Inc. (ZYME) Q3 2024 Earnings Call Transcript	seekingalpha.com
18:20	Zymeworks Inc. (ZYME) Reports Q3 Loss, Lags Revenue Estimates	zacks.com
Tuesday, 29 October 2024
06:00	Zymeworks Announces Participation in Upcoming Investor Conferences	globenewswire.com
Friday, 25 October 2024
06:00	Zymeworks Presents New Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference	globenewswire.com
Monday, 21 October 2024
06:00	Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW171 in Advanced Mesothelin-Expressing Cancers	globenewswire.com
Thursday, 10 October 2024
06:30	Zymeworks to Report Third Quarter 2024 Financial Results and Host Conference Call on October 31, 2024	globenewswire.com
Friday, 27 September 2024
14:47	Zymeworks Approaching A Moment Of Truth With Zanidatamab	seekingalpha.com
Wednesday, 18 September 2024
06:00	Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference	globenewswire.com
Tuesday, 3 September 2024
16:30	Zymeworks Reports Inducement Grant Under Nasdaq Stock Market Rule 5635(c)	globenewswire.com
Thursday, 22 August 2024
06:30	Zymeworks Announces Participation in Upcoming Investor Conferences	globenewswire.com
Thursday, 1 August 2024
22:58	Zymeworks Inc. (ZYME) Q2 2024 Earnings Call Transcript	seekingalpha.com
19:11	Zymeworks Inc. (ZYME) Reports Q2 Loss, Misses Revenue Estimates	zacks.com
16:10	Zymeworks Announces Share Repurchase Program of up to $60 Million of its Common Stock	globenewswire.com
Tuesday, 30 July 2024
06:30	Zymeworks Announces Participation in Upcoming Investor Conferences	globenewswire.com
Thursday, 25 July 2024
16:30	Zymeworks Appoints Leone Patterson as Chief Business and Financial Officer	globenewswire.com
Monday, 22 July 2024
06:00	Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW191, a Novel Folate Receptor-⍺ Targeted Topoisomerase I Inhibitor Antibody-Drug Conjugate	globenewswire.com
Thursday, 11 July 2024
06:30	Zymeworks To Report Second Quarter 2024 Financial Results and Host Conference Call on August 1, 2024	globenewswire.com
Monday, 17 June 2024
06:00	Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW171, a novel 2+1 T-cell Targeting Bispecific Antibody for Mesothelin-expressing Cancers	globenewswire.com
Monday, 10 June 2024
06:00	Zymeworks Announces China NMPA Acceptance of Biologics License Application for Zanidatamab for Second-Line Treatment of Biliary Tract Cancer	globenewswire.com
Friday, 31 May 2024
07:30	Zymeworks Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details- ZYME	accesswire.com
Tuesday, 28 May 2024
06:30	Zymeworks Announces Participation in Upcoming Investor Conferences	globenewswire.com
Sunday, 19 May 2024
22:10	Levi & Korsinsky Reminds Zymeworks Investors of the Ongoing Investigation into Potential Violations of Securities Laws - ZYME	accesswire.com
Friday, 17 May 2024
07:30	Lost Money on Zymeworks Inc.(ZYME)? You May Have Been Affected by Fraud- Contact Levi & Korsinsky	accesswire.com
Thursday, 16 May 2024
16:20	Kirby McInerney LLP is Investigating Potential Shareholder Claims Against Zymeworks Inc. (ZYME)	businesswire.com

Ideas & Opinions

Seeking Alpha 7 Jul 2025

Jazz Pharmaceuticals: I See Big Potential In This Stock As An Investor
Seeking Alpha 12 Jun 2025

Zymeworks: Early-Stage Biotech Feel Despite Zanidatamab Advancements (Downgrade)
Seeking Alpha 28 Apr 2025

Zymeworks: A Strong Buy With Newly-Approved Cancer Drug, Excellent Financials, And Expansive Pipeline
Seeking Alpha 28 Apr 2025

Zymeworks: Poised For Growth With Platform Validation
Seeking Alpha 22 Jan 2025

3 Biotech Stocks With Notable Insider Buying
Seeking Alpha 23 Dec 2024

Jazz Pharmaceuticals: Should Sing A Better Tune In 2025
Seeking Alpha 19 Dec 2024

Zymeworks: Prime Time For Ziihera, Early-Stage Pipeline Progressing Ahead Of Schedule
Seeking Alpha 21 Jun 2024

Jazz Pharmaceuticals: Pipeline Setback While Business Transition Continues
Seeking Alpha 18 Apr 2024

Buy Zymeworks Pioneering Cancer Treatments: Zanidatamab's Promising Data
Seeking Alpha 6 Feb 2024

Zymeworks: Key Readout For Zanidatamab This Year And ADC Pipeline Expansion

Frequently Asked Questions (FAQ)

What's the price of Zymeworks stock today?

One share of Zymeworks stock can currently be purchased for approximately $14.1.
When is Zymeworks's next earnings date?

Unfortunately, Zymeworks's (ZYME) next earnings date is currently unknown.
Does Zymeworks pay dividends?

No, Zymeworks does not pay dividends.
How much money does Zymeworks make?

Zymeworks has a market capitalization of 954.64M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 81.57% to 76.01M US dollars. Zymeworks made a loss 118.67M US dollars in net income (profit) last year or -$0.41 on an earnings per share basis.
What is Zymeworks's stock symbol?

Zymeworks Inc. is traded on the NYSE under the ticker symbol "ZYME".
What is Zymeworks's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Zymeworks?

Shares of Zymeworks can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Zymeworks's key executives?
Zymeworks's management team includes the following people:
- Dr. Ali Tehrani Co-Founder, Pres, Chief Executive Officer & Director(age: 53, pay: $877,660)
- Dr. Anthony J. Polverino Ph.D. Chief Scientific Officer & Executive Vice President of Early Devel.(age: 62, pay: $606,710)
- Mr. Neil A. Klompas C.A., CPA, CPA, CA Executive Vice President of Bus. Operations & Chief Financial Officer(age: 53, pay: $589,860)
- Ms. Kathryn O'Driscoll Chief People Officer(age: 61, pay: $497,220)
Is Zymeworks founder-led company?

Yes, Zymeworks is a company led by its founder Dr. Ali Tehrani.
How many employees does Zymeworks have?

As Jul 2024, Zymeworks employs 275 workers, which is 1% more then previous quarter.
When Zymeworks went public?

Zymeworks Inc. is publicly traded company for more then 8 years since IPO on 28 Apr 2017.
What is Zymeworks's official website?

The official website for Zymeworks is zymeworks.com.
Where are Zymeworks's headquarters?

Zymeworks is headquartered at 114 East 4th Avenue, Vancouver, BC.
How can i contact Zymeworks?

Zymeworks's mailing address is 114 East 4th Avenue, Vancouver, BC and company can be reached via phone at +1 604 678 1388.
What is Zymeworks stock forecast & price target?

Based on 5 Wall Street analysts` predicted price targets for Zymeworks in the last 12 months, the avarage price target is $18.17. The average price target represents a 28.84% change from the last price of $14.1.

Zymeworks Inc.

zymeworks.com

Exchange:

NYSE

Full time employees:

294

Industry:

Biotechnology

Sector:

Healthcare

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and ZW49, a biparatopic anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; BeiGene, Ltd.; and Exelixis, Inc. It also has licensing and research collaboration with LEO Pharma A/S to research, develop, and commercialize bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was incorporated in 2003 and is headquartered in Vancouver, Canada.

+1 604 678 1388

114 East 4th Avenue
Vancouver, BC V5T 1G4

CIK: 0001403752
ISIN: US98985Y1082
CUSIP: 98985W102